英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
46580查看　46580　在百度字典中的解释百度英翻中〔查看〕
46580查看　46580　在Google字典中的解释Google英翻中〔查看〕
46580查看　46580　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • Package Insert - ADSTILADRIN
    ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS
  • U. S. FDA Approves Label Update to Accelerate Thaw Time for . . .
    ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta T1)
  • NCCN upgrades recommendation for nadofaragene firadenovec in . . .
    An update to the 2026 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology has elevated the recommendation for nadofaragene firadenovec-vncg (Adstiladrin) in select patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC), Ferring Pharmaceuticals announced in a news release 1
  • Ferring Announces Update to NCCN Guidelines Expanding . . .
    About ADSTILADRIN ADSTILADRIN ® (nadofaragene firadenovec-vncg) is an FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta T1)
  • Nadofaragene firadenovec-vncg (ADSTILADRIN) National Drug . . .
    Nadofaragene firadenovec uses a recombinant adenovirus that encodes for interferon alpha-2b gene Intravesical instillation of interferon alone for bladder cancer produced complete responses that were short lived in previous studies
  • FDA Approval Summary: Nadofaragene Firadenovec-vncg for . . .
    Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) The product represents the first approved adenoviral vector-based gene therapy and
  • Adstiladrin (Nadofaragene Firadenovec-vncg): Uses, Side . . .
    What is Adstiladrin (Nadofaragene Firadenovec-vncg) Used For? Adstiladrin (Nadofaragene Firadenovec-vncg) is a gene therapy specifically indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors
  • Package Insert - ADSTILADRIN
    ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (1)
  • ADSTILADRIN | FDA
    ADSTILADRIN is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS





中文字典-英文字典  2005-2009